by Truveta Staff | Apr 18, 2024 | Technology
In 2019, the US government unveiled the ambitious Ending the HIV Epidemic (EHE) plan, aiming to slash new HIV infections by 90% by 2030. Thanks to advances in antiretroviral therapy (ART), proven models of prevention, and data access, new HIV infections declined 12%...
by Truveta Staff | Apr 17, 2024 | Research, Technology
Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout March 2024 (-32.4%) compared to February 2024. For infants and children, we see a slight increase in respiratory virus-associated hospitalizations; however, rates are...
by Truveta Staff | Apr 8, 2024 | Research, Technology
Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2019 to December 2023. During the early months of the COVID-19 pandemic, the rate of syphilis incidence (e.g., new infection) increased significantly, reaching a...
by Truveta Staff | Apr 4, 2024 | Technology
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta Staff | Apr 2, 2024 | Technology
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
by Truveta Staff | Mar 29, 2024 | Research, Technology
Prior to the new Medicare guidelines going into effect, Truveta Research and Zeke Emanuel, MD, PhD from the University of Pennsylvania, explored the first-time prescribing and dispensing of anti-obesity GLP-1 RA medications for US adults aged 60 to 69 with obesity or...
